Neuromuscular Electrical Stimulation in Adults with Advanced Disease: an Updated Cochrane Systematic Review
Matthew Maddocks,Sarah Jones,William Man,Wei Gao,Irene Higginson,Andrew Wilcock
DOI: https://doi.org/10.1183/13993003.congress-2016.oa4818
IF: 24.3
2016-01-01
European Respiratory Journal
Abstract:Background: Muscle dysfunction and exercise limitation are common symptoms of advanced disease, but can be treated with exercise training. Neuromuscular electrical stimulation (NMES) is one form of training that is acceptable to people with a high symptom burden. In this updated Cochrane review, we assessed the effectiveness of NMES on markers of muscle and exercise performance. Methods: RCTs were identified from searches of The Cochrane Library, MEDLINE, EMBASE, CINAHL and PsycINFO databases to Janurary 2016, citations, conference proceedings and previous reviews. We included trials in adults with advanced chronic respiratory disease, heart failure, and/or thoracic cancer, comparing a NMES programme to no treatment, placebo or an active control. We imposed no language restriction. Results: We identified 17 RCTs involving 903 people (54% male, mean age range 51-71 years). NMES programmes targeted the quadriceps ± other lower limb muscles, but parameters varied considerably. Overall estimates of effect, by standardised mean difference (SMD, 95%CI), were 0.66 (0.27,1.05) for quadriceps strength and 0.51 (0.20,0.82) for lower limb muscle mass. The observed effect on mass differed by assessment modality. For exercise performance the overall effect was inconsistent, with pooled mean differences (MD) of 36m (14,58) for 6MWT, 5.5m (-37.5,48.6) for ISWT, 61.1m (-26.0,148.1) for ESWT and 43.9ml/kg/min (-16.5,104.3) for peak oxygen uptake by CPET. Conclusion: NMES is an effective treatment for lower limb muscle dysfunction in advanced disease. The secondary effect on exercise performance is variable, which likely reflects muscle performance as one of many limiting factors to exercise.